U.K.'s Indivior PLC said it reached a settlement with Endo International PLC and IntelGenx Technologies Corp. which are looking to market a generic version of its opioid addiction treatment in the U.S.
The settlement permits the companies to sell a generic version of Indivior's Suboxone starting Jan. 1, 2023, or earlier under certain circumstances.
The company did not disclose further details and said the settlement was subject to a review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Indivior had reached a similar settlement with Mylan NV in 2017.
Indivior continues to be in multiple other patent infringement lawsuits, including against Dr. Reddy's Laboratories Ltd., Alvogen, Inc. and Teva Pharmaceutical Industries Ltd., who are also looking to sell a copycat version of Suboxone.
A U.S. court had ruled in March that Alvogen's medicine would not infringe on Indivior's patents covering Suboxone, a decision Indivior said it would appeal.
According to Indivior's 2017 annual report, Suboxone had an average market share of 57% in 2017, down from 61% in 2016. The company generated $1.09 billion in sales during 2017 with Suboxone as the main revenue driver.